The DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
Open accessAbstract
BACKGROUND: Monoclonal gammopathy of undetermined significance (MGUS) occurs in approximately 3% of persons 50 years of age or older. METHODS: We studied 1384 patients who were residing in southeastern Minnesota and in whom MGUS was diagnosed at the Mayo Clinic in the period from 1960 through 1994; the median follow-up was 34.1 years (range, 0.0 to 43.6). The primary end point was progression to multiple myeloma or another plasma-cell or lymphoid disorder. RESULTS: During 14,130 person-years of follow-up, MGUS progressed in 147 patients (11%), a rate that was 6.5 times (95% confidence interval [CI], 5.5 to 7.7) as high as the rate in the control population. The risk of progression without accounting for death due to competing causes was 10% at 10 years, 18% at 20 years, 28% at 30 years, 36% at 35 years, and 36% at 40 years. Among patients with IgM MGUS, the presence of two adverse risk factors - namely, an abnormal serum free light-chain ratio (ratio of kappa to lambda free light chains) and a high serum monoclonal protein (M protein) level (≥1.5 g per deciliter) - was associated with a risk of progression at 20 years of 55%, as compared with 41% among patients who had one adverse risk factor and 19% among patients who had neither risk factor. Among patients with non-IgM MGUS, the risk of progression at 20 years was 30% among those who had the two risk factors, 20% among those who had one risk factor, and 7% among those who had neither risk factor. Patients with MGUS had shorter survival than was expected in the control population of Minnesota residents of matched age and sex (median, 8.1 vs. 12.4 years; P<0.001). CONCLUSIONS: Significant differences were noted in the risk of progression between patients with IgM MGUS and those with non-IgM MGUS. Overall survival was shorter among patients with MGUS than was expected in a matched control population. (Funded by the National Cancer Institute.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This tumor does not develop rapidly; instead, it may take decades for symptoms and organ damage to manifest.4-8”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MM is well-described to be universally preceded by precursor states, often decades before it is even diagnosed.”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several epidemiological studies have shown that patients with MGUS and SMM might experience progression to MM over an extremely variable timeframe. Some patients progressed to MM within 2 years of diagnosis, while others may progress after 10 to 20 years or might never progress at all.4-6,75”
From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [4]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationAsymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
A note on quantifying follow-up in studies of failure time
SCHEMPER, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,592
Tutorial in biostatistics: competing risks and multi‐state models
Putter, H., Fiocco, M. F., & Geskus, R. B. (2006) · Statistics in Medicine · doi:10.1002/sim.2712 · Cited by 2,458
A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa01133202 · Cited by 1,475
Self-citationHistory of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Prevalence of monoclonal gammopathy of undetermined significance
Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., & Melton, L. J. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054494 · Cited by 1,423
Self-citation
Flagged first, then by citations
1 of the 30 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Kyle R Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR Conway de Macario E Folds JD Lane HC Nakamura RM eds. Manual of clinical laboratory immunology. 5th ed. Washington DC: ASM Press 1997:156-76.
Cited by
Sorted by citations
Diagnosis and Management of Multiple Myeloma
Cowan, A. J., Green, D. J., Kwok, M., Lee, S., Coffey, D. G., Holmberg, L., Tuazon, S. A., Gopal, A. K., & Libby, E. N. (2022) · JAMA · doi:10.1001/jama.2022.0003 · Cited by 1,082
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Self-citationMultiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 830
Self-citationKittleson, M. M., Ruberg, F. L., Ambardekar, A. V., Brannagan, T. H., Cheng, R. K.-H., Clarke, J. O., Dember, L. M., Frantz, J. G., Hershberger, R. E., Maurer, M. S., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.11.022 · Cited by 679
Systemic immunoglobulin light chain amyloidosis
Merlini, G., Dispenzieri, A. A., Sanchorawala, V., Schönland, S. O., Palladini, G. O., Hawkins, P. N., & Gertz, M. A. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0034-3 · Cited by 557
Self-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Self-citationHillengaß, J., Usmani, S. Z., Rajkumar, S. V., Durie, B. G. M., Mateos, M., Lonial, S., Joao, C. M., Anderson, K. C., García‐Sánz, R., Riva, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30309-2 · Cited by 549
Self-citationEbeling, P. R., Nguyen, H. H., Aleksova, J., Vincent, A. J., Wong, P., & Milat, F. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab028 · Cited by 368
Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications
Fermand, J., Bridoux, F., Dispenzieri, A. A., Jaccard, A., Kyle, R. A., Leung, N., & Merlini, G. (2018) · Blood · doi:10.1182/blood-2018-04-839480 · Cited by 299
Self-citationRandomized trial of lenalidomide versus observation in smoldering multiple myeloma
Lonial, S., Jacobus, S., Fonseca, R., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A. M., Buadi, F. K., O’Brien, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01740 · Cited by 908
Self-citationMultiple Myeloma: Available Therapies and Causes of Drug Resistance
Pinto, V., Bergantim, R., Caires, H. R., Seca, H., Guimarães, J. E., & Vasconcelos, M. H. (2020) · Cancers · doi:10.3390/cancers12020407 · Cited by 241
Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2018) · American Journal of Hematology · doi:10.1002/ajh.25117 · Cited by 229
Self-citationSystemic Light Chain Amyloidosis
Sanchorawala, V. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2304088 · Cited by 174
Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma
Barwick, B. G., Gupta, V. A., Vertino, P. M., & Boise, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01121 · Cited by 184
Kieseier, B. C., Mathey, E. K., Sommer, C., & Hartung, H. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0027-2 · Cited by 155
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis
Kastritis, E., Leleu, X. P., Arnulf, B., Zamagni, E., Cibeira, M. T., Kwok, F., Mollee, P. N., Hájek, R., Moreau, P., Jaccard, A., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01285 · Cited by 150
Imaging in multiple myeloma: How? When?
Zamagni, E., Tacchetti, P., & Cavo, M. (2018) · Blood · doi:10.1182/blood-2018-08-825356 · Cited by 138
Roadmap to cure multiple myeloma
Rodríguez‐Otero, P., Paiva, B., & Miguel, J. F. S. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102284 · Cited by 146
Long, T. E., Indridason, Ó. S., Pálsson, R., Rögnvaldsson, S., Löve, Þ. J., Þorsteinsdóttir, S., Sverrisdottir, I. S., Viðarsson, B., Onundarson, P. T., Agnarsson, B. A., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00732-3 · Cited by 132
Sanoja-Flores, L., Flores-Montero, J. A., Garcés, J., Paiva, B., Puig, N., García‐Mateo, A., García-Sánchez, O., Corral-Mateos, A., Burgos, L., Blanco, E., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0153-9 · Cited by 133
Rögnvaldsson, S., Löve, Þ. J., Þorsteinsdóttir, S., Reed, E. R., Óskarsson, J. Þ., Pétursdóttir, Í., Sigurðardóttir, G. Á., Viðarsson, B., Onundarson, P. T., Agnarsson, B. A., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00480-w · Cited by 129
Oben, B., Froyen, G., Maclachlan, K. H., Leongamornlert, D., Abascal, F., Zheng-Lin, B., Yellapantula, V., Derkach, A., Geerdens, E., Diamond, B. T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22140-0 · Cited by 129
Hepatitis E: an underestimated emerging threat
Webb, G. W., & Dalton, H. R. (2019) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936119837162 · Cited by 127
Levine, A. J., Jenkins, N. A., & Copeland, N. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.11.009 · Cited by 121
Vitamin D Deficiency, Osteoporosis and Effect on Autoimmune Diseases and Hematopoiesis: A Review
Martinis, M. D., Allegra, A., Sirufo, M. M., Tonacci, A., Pioggia, G., Raggiunti, M., Ginaldi, L., & Gangemi, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168855 · Cited by 133
Vergaro, G., Aimo, A., Barison, A., Genovesi, D., Buda, G., Passino, C., & Emdin, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319877708 · Cited by 116
Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment
Gertz, M. A. (2023) · American Journal of Hematology · doi:10.1002/ajh.27177 · Cited by 112
Landgren, O., Hofmann, J. N., McShane, C. M., Santo, L., Hultcrantz, M., Korde, N., Mailankody, S., Kazandjian, D., Murata, K., Thoren, K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1568 · Cited by 103
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment
Gertz, M. A. (2022) · American Journal of Hematology · doi:10.1002/ajh.26569 · Cited by 103
Murray, D., Kumar, S. K., Kyle, R. A., Dispenzieri, A., Dasari, S., Larson, D. R., Vachon, C., Cerhan, J. R., & Rajkumar, S. V. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0263-z · Cited by 102
Self-citationProgression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia
Bustoros, M. W., Sklavenitis‐Pistofidis, R., Kapoor, P., Liu, C., Kastritis, E., Zanwar, S., Fell, G. G., Abeykoon, J. P., Hornburg, K., Neuse, C. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00394 · Cited by 99
Self-citationNew Insights from Studies of Clonal Hematopoiesis
Gibson, C. J., & Steensma, D. P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3044 · Cited by 97
Monoclonal gammopathy of undetermined significance
Mouhieddine, T. H., Weeks, L. D., & Ghobrial, I. M. (2019) · Blood · doi:10.1182/blood.2019846782 · Cited by 93
Prevalence of smoldering multiple myeloma based on nationwide screening
Thorsteinsdóttir, S., Gíslason, G. K., Aspelund, T., Rögnvaldsson, S., Óskarsson, J. Þ., Sigurðardóttir, G. Á., Þórðardóttir, Á. R., Viðarsson, B., Önundarson, P. T., Agnarsson, B. A., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02183-6 · Cited by 93
Management of acute kidney injury in symptomatic multiple myeloma
Bridoux, F., Leung, N., Belmouaz, M., Royal, V., Ronco, P. M., Nasr, S. H., & Fermand, J. P. (2021) · Kidney International · doi:10.1016/j.kint.2020.11.010 · Cited by 85
AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies
Bianchi, G., Zhang, Y., & Comenzo, R. L. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2021.09.003 · Cited by 83
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management
Gertz, M. A. (2020) · American Journal of Hematology · doi:10.1002/ajh.26082 · Cited by 83
Multiple Myeloma Therapy: Emerging Trends and Challenges
Dima, D., Jiang, D., Singh, D. J., Hasipek, M., Shah, H., Ullah, F., Khouri, J., Maciejewski, J. P., & Jha, B. K. (2022) · Cancers · doi:10.3390/cancers14174082 · Cited by 92
Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management
Gertz, M. A. (2018) · American Journal of Hematology · doi:10.1002/ajh.25292 · Cited by 77
Boiarsky, R. P., Haradhvala, N. J., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Mouhieddine, T. H., Zavidij, O., Shih, M., Firer, D. T., Miller, M. L., El‐Khoury, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33944-z · Cited by 80
Smoldering multiple myeloma current treatment algorithms
Rajkumar, S. V., Kumar, S. K., Lonial, S., & Mateos, M. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00719-0 · Cited by 76
Self-citationIgM monoclonal gammopathies of clinical significance: diagnosis and management
Khwaja, J., D’Sa, S., Minnema, M. C., Kersten, M. J., Wechalekar, A. D., & Vos, J. M. I. (2022) · Haematologica · doi:10.3324/haematol.2022.280953 · Cited by 76
Plasma cell neoplasms and related entities—evolution in diagnosis and classification
Fend, F., Doǧan, A., & Cook, J. R. (2022) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-022-03431-3 · Cited by 86
Abduh, M. S. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103920 · Cited by 65
PD-L1–PD-1 Pathway in the Pathophysiology of Multiple Myeloma
Tamura, H., Ishibashi, M., Sunakawa-Kii, M., & Inokuchi, K. (2020) · Cancers · doi:10.3390/cancers12040924 · Cited by 67
Nativi-Nicolau, J. N., & Maurer, M. S. (2018) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000547 · Cited by 65
Laboratory Detection and Initial Diagnosis of Monoclonal Gammopathies
Keren, D. F., Bocsi, G., Billman, B. L., Etzell, J., Faix, J. D., Kumar, S., Lipe, B. C., McCudden, C. R., Montgomery, R., Murray, D. L., et al. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0794-cp · Cited by 65
Self-citationEmerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
Zhang, K. W., Stockerl-Goldstein, K. E., & Lenihan, D. J. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.02.002 · Cited by 62
Systemic AL Amyloidosis: Current Approaches to Diagnosis and Management
Fotiou, D., Dimopoulos, M. A., & Kastritis, E. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000454 · Cited by 60
Amyloidosis as a Systemic Disease in Context
Cuddy, S. A. M., & Falk, R. H. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2019.12.033 · Cited by 59
Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
Visram, A., Soof, C. M., Rajkumar, S. V., Kumar, S. K., Bujarski, S. E., Spektor, T. M., Kyle, R. A., Berenson, J. R., & Dispenzieri, A. A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00505-4 · Cited by 58
Self-citationCutaneous manifestations of monoclonal gammopathy
Claveau, J., Wetter, D. A., & Kumar, S. K. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00661-1 · Cited by 55
Self-citationLandgren, O., Zeig-Owens, R., Giricz, O., Goldfarb, D., Murata, K., Thoren, K., Ramanathan, L., Hultcrantz, M., Dogan, A., Nwankwo, G., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0509 · Cited by 55
Termini, R., Žihala, D., Terpos, E., Perez-Montaña, A., Jelínek, T., Raab, M., Weinhold, N., Mai, E. K., Grab, A. L., Corre, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1594 · Cited by 54
Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 61
Bone marrow inflammation in haematological malignancies
de Jong, M. M. E., Chen, L., Raaijmakers, M. H. G. P., & Cupedo, T. (2024) · Nature reviews. Immunology · doi:10.1038/s41577-024-01003-x · Cited by 54
Neuromuscular amyloidosis: Unmasking the master of disguise
Pinto, M. V., Dyck, P. J. B., & Liewluck, T. (2021) · Muscle & Nerve · doi:10.1002/mus.27150 · Cited by 53
Hester, L., Gifkins, D., Bellew, K. M., VERMEULEN, J. T., Schecter, J. M., Strony, J. T., Dishy, V., & Weiss, B. M. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13679 · Cited by 55
Genomic Instability in Multiple Myeloma
Alagpulinsa, D. A., Szalat, R. E., Poznansky, M. C., & Reis, R. J. S. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.05.006 · Cited by 53
Dogliotti, I., Jiménez, C., Varettoni, M., Talaulikar, D., Bagratuni, T., Ferrante, M., Pérez, J. J., Drandi, D., Puig, N., Gilestro, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01762-3 · Cited by 51
Free light chains and autoimmunity
Napodano, C., Pocino, K., Rigante, D., Stefanile, A., Gulli, F., Marino, M., Basile, V., Rapaccini, G. L., & Basile, U. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.03.003 · Cited by 51
Bergstrom, D. J., Kotb, R. R., Louzada, M., Sutherland, H. J., Tavoularis, S., Venner, C. P., Côté, J. A., LeBlanc, R., Reiman, T., Sébag, M., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.01.017 · Cited by 51
Singh, G. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfaa153 · Cited by 48
Gozzetti, A., Guarnieri, A., Zamagni, E., Zakharova, E., Coriu, D., Bittrich, M., Pika, T., Tovar, N., Schutz, N. P., Ciofini, S., et al. (2022) · American Journal of Hematology · doi:10.1002/ajh.26566 · Cited by 48
Systemic AL amyloidosis: current approach and future direction
Zerdan, M. B., Nasr, L. F., Khalid, F., Allam, S., Bouferraa, Y., Batool, S., Tayyeb, M., Adroja, S., Mammadii, M., Anwer, F., et al. (2023) · Oncotarget · doi:10.18632/oncotarget.28415 · Cited by 47
Interest of Pet Imaging in Multiple Myeloma
Jamet, B., Bailly, C., Carlier, T., Touzeau, C., Nanni, C., Zamagni, E., Barré, L., Michaud, A.-V., Chérel, M., Moreau, P., et al. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00069 · Cited by 50
Lecouvet, F. E., Vekemans, M., Berghe, T. V. D., Verstraete, K. L., Kirchgesner, T., Acid, S., Malghem, J. J., Wuts, J., Hillengaß, J., Vandecaveye, V., et al. (2021) · Skeletal Radiology · doi:10.1007/s00256-021-03841-5 · Cited by 46
Monoclonal Gammopathy of Undetermined Significance (MGUS)—Not So Asymptomatic after All
Lomas, O., Mouhieddine, T. H., Tahri, S., & Ghobrial, I. M. (2020) · Cancers · doi:10.3390/cancers12061554 · Cited by 46
Game of Bones: How Myeloma Manipulates Its Microenvironment
Moser-Katz, T., Joseph, N. S., Dhodapkar, M. V., Lee, K. P., & Boise, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.625199 · Cited by 50
Nair, S., Bar, N., Xu, M. L., Dhodapkar, M. V., & Mistry, P. K. (2020) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2020.01.009 · Cited by 44
Role of imaging in multiple myeloma
Baffour, F. I., Glazebrook, K. N., Kumar, S. K., & Broski, S. M. (2020) · American Journal of Hematology · doi:10.1002/ajh.25846 · Cited by 43
Self-citationPreneoplastic somatic mutations including MYD88 L265P in lymphoplasmacytic lymphoma
Rodríguez, S., Celay, J., Goicoechea, I., Jiménez, C., Botta, C., Garcia-Barchino, M. J., Garcés, J., Larráyoz, M., Santos, S. A., Alignani, D., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl4644 · Cited by 47
Clonal haematopoiesis, ageing and kidney disease
Vlasschaert, C., Lanktree, M. B., Rauh, M. J., Kelly, T. N., & Natarajan, P. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00778-x · Cited by 42
Rosenbloom, B. E., Cappellini, M. D., Weinreb, N. J., Dragosky, M. O., Revel‐Vilk, S., Batista, J. L., Sekulić, D., & Mistry, P. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26675 · Cited by 41
New Biological Therapies for Multiple Myeloma
Garfall, A. L. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-050522-033815 · Cited by 47
Defining precancer: a grand challenge for the cancer community
Faupel‐Badger, J. M., Kohaar, I., Bahl, M., Chan, A. T., Campbell, J. D., Li, J., Marzo, A. M. D., Maitra, A., Merrick, D. T., Hawk, E. T., et al. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00744-0 · Cited by 46
Genome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 43
Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance
Liu, Y., & Parks, A. L. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.8124 · Cited by 38
Cuscaden, C., Ramsay, S. C., Prasad, S. B., Goodwin, B., & Smith, J. (2020) · Journal of Nuclear Cardiology · doi:10.1007/s12350-020-02152-x · Cited by 38
Extramedullary Multiple Myeloma: Challenges and Opportunities
Ho, M., Paruzzo, L., Minehart, J. C., Nabar, N. R., Noll, J. H., Luo, T., Garfall, A. L., & Zanwar, S. (2025) · Current Oncology · doi:10.3390/curroncol32030182 · Cited by 39
Mikhael, J. R., Bhutani, M., & Cole, C. E. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.08.030 · Cited by 36
The Proximal Tubule Toxicity of Immunoglobulin Light Chains
Sirac, C., Batuman, V., & Sanders, P. W. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.02.026 · Cited by 35
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Baz, R., Campagnaro, E. L., Castillo, J. J., Costello, C. L., D'Angelo, C. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0001 · Cited by 35
Self-citationPaquin, A. R., Kumar, S. K., Buadi, F. K., Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Hwa, Y. L., Fonder, A. L., Hobbs, M., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0163-7 · Cited by 35
Self-citationNanni, C., Deroose, C. M., Balogová, S., Lapa, C., Withofs, N., Subesinghe, M., Jamet, B., Zamagni, E., Ippolito, D., Delforge, M., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06858-9 · Cited by 37
The Non-Coding RNA Landscape of Plasma Cell Dyscrasias
Morelli, E., Gullà, A., Rocca, R., Federico, C., Raimondi, L., Malvestiti, S., Agosti, V., Rossi, M., Costa, G., Giavaresi, G., et al. (2020) · Cancers · doi:10.3390/cancers12020320 · Cited by 34
Reconstructing the evolutionary history of multiple myeloma
Maura, F., Rustad, E. H., Boyle, E. M., & Morgan, G. J. (2020) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2020.101145 · Cited by 30
Obesity and myeloma: Clinical and mechanistic contributions to disease progression
Marques-Mourlet, C., Iorio, R. D., Fairfield, H. E., & Reagan, M. R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1118691 · Cited by 38
Genomic landscape of multiple myeloma and its precursor conditions
Alberge, J.-B., Dutta, A. K., Poletti, A., Coorens, T. H. H., Lightbody, E. D., Toenges, R., Loinaz, X., Wallin, S., Dunford, A., Priebe, O., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02196-0 · Cited by 32
Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders
Zanwar, S., & Rajkumar, S. V. (2025) · Leukemia · doi:10.1038/s41375-025-02654-y · Cited by 37
Self-citationImpact of prior diagnosis of monoclonal gammopathy on outcomes in newly diagnosed multiple myeloma
Goyal, G., Rajkumar, S. V., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Dispenzieri, A. A., Hwa, Y. L., Fonder, A. L., Hobbs, M., Hayman, S. R., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0419-7 · Cited by 32
Self-citationMesenchymal stromal cell senescence in haematological malignancies
Plakhova, N., Panagopoulos, V., Vandyke, K., Zannettino, A. C. W., & Mrozik, K. M. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10069-9 · Cited by 33
New horizons in our understanding of precursor multiple myeloma and early interception
dos Santos, D. M. C., Toenges, R., Bertamini, L., Alberge, J.-B., & Ghobrial, I. M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00755-x · Cited by 34
Monoclonal gammopathy of undetermined significance
Rajkumar, S. V., & Kumar, S. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2412716 · Cited by 31
Self-citationManagement of Newly Diagnosed Elderly Multiple Myeloma Patients
Antoine-Pepeljugoski, C., & Braunstein, M. J. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0804-4 · Cited by 33
Kleinstern, G., Larson, D. R., Allmer, C., Norman, A. D., Muntifering, G., Sinnwell, J. P., Visram, A., Rajkumar, S. V., Dispenzieri, A. A., Kyle, R. A., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00659-9 · Cited by 33
Self-citationMonoclonal Gammopathies of Clinical Significance: A Critical Appraisal
Ríos, R., Paiva, B., Lahuerta, J. J., Martínez‐López, J., & Duarte, R. F. (2022) · Cancers · doi:10.3390/cancers14215247 · Cited by 31
Brevi, A., Cogrossi, L. L., Lorenzoni, M., Mattorre, B., & Bellone, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.845422 · Cited by 29
Handa, H., Honma, K., Oda, T., Kobayashi, N., Kuroda, Y., Kimura-Masuda, K., Watanabe, S., Ishihara, R., Murakami, Y., Masuda, Y., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197121 · Cited by 28
Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma
Bashiri, H., & Tabatabaeian, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076019 · Cited by 30
Metadata
- Authors
- Kyle, R. A., Larson, D. R., Therneau, T. M., Dispenzieri, A., Kumar, S., Cerhan, J. R., & Rajkumar, S. V.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-01-18
- Volume
- 378
- Issue
- 3
- Pages
- 241-249
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5852672
- OpenAlex
- W2785817645
- Cited by
- 647
- References
- 30
- Citations by year
- 2026: 62 · 2025: 90 · 2024: 101 · 2023: 81 · 2022: 75 · 2021: 76 · 2020: 80 · 2019: 47 · 2018: 33
- FWCI
- 42.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA107476, CA168762, CA186781)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, plasma cell dyscrasia, free light chain ratio, risk factors, survival, long-term follow-up
- MeSH terms
- Adult, Aged, Bone Marrow Examination, Female, Follow-Up Studies, Glycoproteins, Humans, Immunoglobulin M, Immunoglobulin Light Chains, Male, Middle Aged, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Prognosis, Risk Factors, Proportional Hazards Models, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
